Developing therapeutics
at the forefront of oncology

About us

What we do

We challenge current treatment paradigms

At Ryvu, we develop therapeutics that address clinical limitations of current treatments in oncology.

Our pipeline includes candidates with differentiated properties from kinase, synthetic lethality, immuno-oncology and immunometabolism programs.

See our Pipeline
KINASE INHIBITORS
Synthetic Lethality
Immuno-Oncology
Cancer Metabolism

Investor Relations

Ryvu Therapeutics (Selvita Oncology) was founded in 2007. Since 2014, the company has been listed on Warsaw Stock Exchange under the ticker SLV.

Ryvu Therapeutics is organized for highly efficient R&D driven by breakthrough science, aiming to realize full value potential for its shareholders, partners and employees.

See More
46.20 PLN +1.99% RVU • 10/12/2019 11:53 • Warsaw Stock Exchange

Let's Grow Together

Do you want to challenge and be challenged?

Do you want to have an impact on the world?
Please see our current openings to learn more about our work.

Join Us